• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email
    SC 13G/A 1 lenz1015247sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Lenz Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

     

    52635N103

    (CUSIP Number)

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    Lenz Therapeutics, Inc., a Delaware corporation, formerly known as Graphite Bio, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA 92075

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management; and Tang Capital Partners, LP (“Tang Capital Partners”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP Number 52635N103

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 27,496,665 shares of Common Stock outstanding as of August 9, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 14, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 2.8%
    Kevin Tang 2.8%
    Tang Capital Partners 2.8%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 766,940 shares
    Kevin Tang 766,940 shares
    Tang Capital Partners 766,940 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 766,940 shares
    Kevin Tang 766,940 shares
    Tang Capital Partners 766,940 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     Page 6 of 8 Pages 
     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $LENZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    3/27/2024$28.00Overweight
    Piper Sandler
    More analyst ratings

    $LENZ
    Financials

    Live finance-specific insights

    See more
    • LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

      5/7/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inve

      4/30/25 4:30:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025 Cash, cash equivalents and marketable securities of $209.1 million as of December 31, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EST SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first a

      3/19/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by LENZ Therapeutics Inc.

      SCHEDULE 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      5/9/25 4:19:30 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by LENZ Therapeutics Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/7/25 4:16:06 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/7/25 4:09:09 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

      Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

      4/14/25 8:17:08 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on LENZ Therapeutics with a new price target

      TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

      3/18/25 7:53:26 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on LENZ Therapeutics with a new price target

      Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00

      9/27/24 7:38:17 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/15/24 4:13:06 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

      SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializing novel pharmaceuticals to provide pa

      5/9/25 9:03:48 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

      5/7/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV. Details of the event are as follows:Date: Tuesday, May 13, 2025Location: Encore Hotel, Las Vegas, NevadaTime: 9:20am PDT / 12:20pm EDT A live audio webcast of the BofA Securities 2025 Health Care Conference present

      5/6/25 4:30:48 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      11/14/24 4:00:05 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

      SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      11/8/24 5:08:56 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by LENZ Therapeutics Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      7/29/24 4:12:50 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Olsson Shawn exercised 1,400 shares at a strike of $2.08, increasing direct ownership by 42% to 4,733 units (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      4/9/25 7:20:28 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, CEO and Secretary Schimmelpennink Evert B. exercised 4,200 shares at a strike of $1.04, increasing direct ownership by 9% to 49,200 units (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/7/25 6:10:43 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Olsson Shawn

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      1/13/25 5:26:58 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lucy Therapeutics Appoints Kim Drapkin as Board Chair

      Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

      10/15/24 8:00:00 AM ET
      $ABOS
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

      Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

      6/10/24 8:00:00 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care